Franny Jongbloed

74 CHAPTER 3 18. Kim, J., Kundu, M., Viollet, B. & Guan, K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat-cell Biol 13, 132-141 (2011). 19. Wang, X.W. & Zhang, Y.J. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol 20, 4178-4188 (2014). 20. Mitchell, J.R., et al. Short-term dietary restriction and fasting precondition against ischemia- reperfusion injury in mice. Aging Cell 9, 40-53 (2010). 21. Jaramillo, M.C. & Zhang, D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27, 2179-2191 (2013). 22. Moon, E.J. & Giaccia, A. Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment. Free Radic Biol Med 79, 292-299 (2015). 23. Fontana, L., Partridge, L. & Longo, V.D. Extending healthy life span--from yeast to humans. Science 328, 321-326 (2010). 24. Laizure, S.C., Herring, V., Hu, Z.,Witbrodt, K. &Parker, R.B.The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33, 210-222 (2013). 25. Etienne-Grimaldi, M.C., et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol 29, 219-237 (2015). 26. Cortejoso, L. & Lopez-Fernandez, L.A. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 13, 1173-1191 (2012). 27. Innocenti, F., et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27, 2604-2614 (2009). 28. de Jong, F.A., Kitzen, J.J., de Bruijn, P., Verweij, J. & Loos, W.J. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 5, 1105-1110 (2006). 29. Li, M., et al. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 7, 1653-1661 (2014). 30. Cecchin, E., et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27, 2457-2465 (2009). 31. Moll, U.M. & Petrenko, O. The MDM2-p53 interaction. Mol Cancer Res 1, 1001-1008 (2003). 32. Eijssen, L.M., et al. User-friendly solutions for microarray quality control and pre-processing on ArrayAnalysis.org. Nucleic Acids Res 41, W71-76 (2013). 33. Irizarry, R.A., et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15 (2003). 34. Green, G.H. & Diggle, P.J. On the operational characteristics of the Benjamini and Hochberg False Discovery Rate procedure. Stat Appl Genet Mol Biol 6, Article27 (2007).